新型单克隆抗体LMab-4检测口腔癌中高程序性死亡受体配体1（PD-L1）表达
Detection of high PD-L1 expression in oral cancers by a novel monoclonal antibody LMab-4.
作者信息
Yamada Shinji, Itai Shunsuke, Kaneko Mika K, Kato Yukinari
机构信息
Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8575, Japan.
出版信息
Biochem Biophys Rep. 2018 Feb 6;13:123-128. doi: 10.1016/j.bbrep.2018.01.009. eCollection 2018 Mar.
Programmed cell death-ligand 1 (PD-L1), which is a ligand of programmed cell death-1 (PD-1), is a type I transmembrane glycoprotein that is expressed on antigen-presenting cells and several tumor cells, including melanoma and lung cancer cells. There is a strong correlation between human PD-L1 (hPD-L1) expression on tumor cells and negative prognosis in cancer patients. In this study, we produced a novel anti-hPD-L1 monoclonal antibody (mAb), LMab-4 (IgG, kappa), using cell-based immunization and screening (CBIS) method and investigated hPD-L1 expression in oral cancers. LMab-4 reacted with oral cancer cell lines (Ca9-22, HO-1-u-1, SAS, HSC-2, HSC-3, and HSC-4) in flow cytometry and stained oral cancers in a membrane-staining pattern. LMab-4 stained 106/150 (70.7%) of oral squamous cell carcinomas, indicating the very high sensitivity of LMab-4. These results indicate that LMab-4 could be useful for investigating the function of hPD-L1 in oral cancers.
程序性细胞死亡配体1（PD-L1）是程序性细胞死亡蛋白1（PD-1）的配体，是一种I型跨膜糖蛋白，在抗原呈递细胞和多种肿瘤细胞（包括黑色素瘤细胞和肺癌细胞）上表达。肿瘤细胞上的人PD-L1（hPD-L1）表达与癌症患者的不良预后之间存在密切关联。在本研究中，我们采用基于细胞的免疫接种和筛选（CBIS）方法制备了一种新型抗hPD-L1单克隆抗体（mAb）LMab-4（IgG，κ），并研究了hPD-L1在口腔癌中的表达。LMab-4在流式细胞术中与口腔癌细胞系（Ca9-22、HO-1-u-1、SAS、HSC-2、HSC-3和HSC-4）发生反应，并以膜染色模式对口腔癌进行染色。LMab-4对106/150例（70.7%）口腔鳞状细胞癌进行了染色，表明LMab-4具有很高的敏感性。这些结果表明，LMab-4可用于研究hPD-L1在口腔癌中的功能。
Zotero 插件